Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
KYTH > SEC Filings for KYTH > Form 8-K on 2-Apr-2013All Recent SEC Filings

Show all filings for KYTHERA BIOPHARMACEUTICALS INC | Request a Trial to NEW EDGAR Online Pro

Form 8-K for KYTHERA BIOPHARMACEUTICALS INC


2-Apr-2013

Change in Directors or Principal Officers, Financial Statements an


Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 27, 2013, KYTHERA Biopharmaceuticals, Inc. (the "Company") entered into a separation agreement and release with Patricia Walker, M.D., Ph.D., the Company's former Chief Medical Officer (the "Separation Agreement"). The Separation Agreement provides that Dr. Walker will receive benefits consistent with her Amended and Restated Employment Agreement with the Company, dated April 2, 2012, which include (a) a lump sum cash payment equal to six months of her effective base salary, or $179,000, (b) reimbursement by the Company of Dr. Walker's COBRA premiums through September 22, 2013 and (c) a payment equal to 50% of the Company contribution for 2013 for any healthcare savings account in which Dr. Walker participates. The receipt of the foregoing benefits is conditioned upon Dr. Walker's nonrevocation of the Separation Agreement.

In addition, on March 28, 2013, the Company entered into an advisory agreement with Dr. Walker as a Senior Advisor to the Company's Board of Directors (the "Advisory Agreement") pursuant to which Dr. Walker has agreed to provide certain advisory services to the Company through March 27, 2014 in support of the Company's clinical and regulatory development programs and the transition to the Company's new Chief Medical Officer, Frederick Beddingfield III, M.D., Ph.D. In exchange for her services under the Advisory Agreement, Dr. Walker is entitled to (a) an upfront cash payment of approximately $26,650, (b) a monthly retainer of $13,000, (c) $520 per hour for any services requested in excess of 28 hours worked per month, (d) reimbursement by the Company of COBRA premiums from September 28, 2013 through March 27, 2014 (if not already covered by a similar health plan) and (e) continued vesting of her previously granted stock options at a rate of 2,000 shares per month for the initial 6 months and 1,000 shares per month for the remaining 6 months under the term of the Advisory Agreement. Dr. Walker has agreed to certain restrictions on consulting and other activities related to the Company's field during the term of the Advisory Agreement. Additionally, in the event of a Change of Control (as defined in the Advisory Agreement), Dr. Walker shall be entitled to (i) a lump sum equal to the unpaid retainer (assuming a 12 month term) and (ii) immediate vesting of 100% of the remaining unvested equity awards described in (e) above. The receipt of the change of control benefits described above is conditioned upon Dr. Walker's timely execution and nonrevocation of a release in favor of and satisfactory to the Company. The Advisory Agreement may be terminated by either party upon 30 days' written notice or immediately by the Company upon a material breach of the agreement or in the event Dr. Walker revokes her acceptance of the Separation Agreement.

The foregoing description of the material terms of the Separation Agreement and the Advisory Agreement is qualified in its entirety by the terms of such agreements, which are filed herewith as Exhibits 10.1 and 10.2, respectively.



Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.                                Description

10.1             Separation Agreement and Release, dated March 27, 2013, by and
                 between Patricia Walker, M.D., Ph.D., and KYTHERA
                 Biopharmaceuticals, Inc.
10.2             Senior Advisor to the Board of Directors Agreement, effective
                 March 28, 2013, by and between Patricia Walker, M.D., Ph.D.,
                 and KYTHERA Biopharmaceuticals, Inc.


  Add KYTH to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for KYTH - All Recent SEC Filings
Sign Up for a Free Trial to the NEW EDGAR Online Pro
Detailed SEC, Financial, Ownership and Offering Data on over 12,000 U.S. Public Companies.
Actionable and easy-to-use with searching, alerting, downloading and more.
Request a Trial      Sign Up Now


Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.